Clinical Trial Update: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study of LHA510 as maintenance therapy for wet age-related macular degeneration has completed. Results were posted on 2017-11-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• LHA510

Snippet

Sponsor: Alcon, a Novartis Company | Conditions: Exudative Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2017-11-14